In a study involving six human thyroid cancer cell lines, Park et al. (56) found that troglitazone downregulated the surface expression of CD97, a novel dedifferentiation marker, in FTC-133 cells and upregulated NIS mRNA in TPC-1 and FTC-133 cells. Here, SLC5A5 is linked to thyroid gland carcinoma.